Diagnosing coinfection in pneumonia can be challenging because of timing of the sample collection and false-negative results when the viruses replicate in the lower respiratory tract.
Researchers found limited clinical variability between PIV serotypes and substantial overlap in presenting signs and symptoms for PIV and other etiologies.
A phase 3 study of tocilizumab (Actemra®) for the treatment of hospitalized patients with severe COVID-19 pneumonia did not meet its primary and key secondary end points.
Treatment with mavrilimumab is associated with improved clinical outcomes compared with standard care in non-mechanically ventilated patients with severe COVID-19 pneumonia and systemic hyperinflammation.
Preliminary data demonstrated that the Unyvero HPN panel was strongly concordant with bacterial culture for organism targets, confirming all pathogens reported by culture in 31 out of 35 patient samples.
Pediatric HIV infection and HIV exposure without infection both had an association with carriage prevalence and densities for Streptococcus pneumoniae and Pneumocystis jirovecii.
Trimethoprim-sulfamethoxazole (TMP-SMX) for Pneumocystis jirovecii pneumonia (PCP) prophylaxis in combination with methotrexate (MTX) was shown to be successful and well-tolerated in patients with chronic inflammatory/autoimmune diseases.
Merck announced results from the phase 3 RESTORE-IMI 2 trial of imipenem/relebactam/cilastatin (Recarbrio™) for the treatment of adults with hospital-acquired or ventilator-associated bacterial pneumonia (HABP/VABP).
A parsimonious score system that accurately identified elderly and non-elderly patients with pneumonia at highest risk for mortality in the intensive care unit has been developed.
The FDA has accepted for review a sNDA for Recarbrio™, to treat adult patients with hospital-acquired and ventilator-associated bacterial pneumonia.
Inhaled amikacin adjunctive to standard-of-care intravenous antibiotic therapy was not associated with improvements in survival in mechanically ventilated patients with Gram-negative pneumonia.
Microbiologic treatment failure was found to be independently associated with recurrent pneumonia or death among patients with bacterial pneumonia after clinical cure.
